Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase lb/ll, Open Label, Single Arm Study to Assess Efficacy and Safety of Alpelisib and Capecitabine in Patients With PIK3CA Mutant Metastatic Colorectal Cancer Who Failed Two Prior Standard Chemotherapies

NCT04753203 is registered in ClinicalTrials.gov with Korean Cancer Study Group as lead sponsor.

NCT NCT04753203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04753203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase lb/ll, Open Label, Single Arm Study to Assess Efficacy and Safety of Alpelisib and Capecitabine in Patients With PIK3CA Mutant Metastatic Colorectal Cancer Who Failed Two Prior Standard Chemotherapies
Lead sponsor
Korean Cancer Study Group
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 28, 2021
Completion date
February 28, 2025
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer, pik3ca gene mutation